info@seagull-health.com
SeagullHealth
search
Crizotinib(Crizalk)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
XALKORI(Crizotinib) Instructions:Uses,Dosage, Side Effects
XALKORI is a prescription medication available in capsule and pellet forms, designed to inhibit kinases such as ALK, ROS1, and MET. It is used in adults and children over one year old for the treatment of metastatic non-small cell lung cancer (NSCLC), systemic anaplastic large cell lymphoma (ALCL), and inflammatory myofibroblastic tumor (IMT), provided these cancers are ALK or ROS1-positive. It was first approved in the U.S. in 2011.
Metastatic non-small cell lung cancer (NSCLC) in adults with ALK or ROS1 positivity.
Relapsed or refractory systemic ALK-positive anaplastic large cell lymphoma (ALCL) in patients ≥1 year old.
Unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumor (IMT) in patients ≥1 year old.
NSCLC (adults): 250 mg orally twice daily.
ALCL (pediatric/young adults): 280 mg/m² orally twice daily (based on BSA).
IMT (adults): 250 mg twice daily.
IMT (pediatric): 280 mg/m² twice daily (based on BSA).
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
